On December 28, 2021, biopharmaceutical CDMO and cell culture biotechnology company Thousand Oaks announced the closing of a new round of financing of RMB 1.5 billion. The round was led by shareholders Goldstone Fund and CDH Investments, with participation from several leading institutions.

CEC Capital Group served as the exclusive financial advisor in this transaction.

Thousand Oaks is committed to being a leader in China's biopharmaceutical industry, integrating raw materials, consumables, pharmaceutical equipment, technical services, and contract manufacturing. The company specializes in CMC biomanufacturing, providing customers with a one-stop service of "research and development - process - production - logistics - technical support - after-sales."